196
Participants
Start Date
November 30, 2016
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2027
CRT
"Drug: Capecitabine(Aibin) capecitabine(Aibin):625mg/m2, bid d1-5; q1w, po,5 weeks in total~Other Names:~Aibin Drug: Oxaliplatin(Aiheng) Oxaliplatin(Aiheng):65mg/m2,d1,8, 22, 29,I.V.~Other Names:~Aiheng cisplatin: 75mg/m2 d1,29 or d1, 29, 57, 85. 5-Fu:750mg/m2 CIV24h d1-4,d29-32 or d1-4,d29-32, d57-60, d85-88.~Radiation: Radiotherapy concurrent radiotherapy:IMRT radiotherapy 50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity"
surgery
The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
RECRUITING
The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang
RECRUITING
Anyang Tumor Hospital, Anyang
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY
Anyang Tumor Hospital
OTHER
150th Hospital of PLA
OTHER_GOV
The First Affiliated Hospital of Henan University of Science and Technology
OTHER